Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Oct 2, 2024
Management Tracks
IGM names Mary Beth Harler CEO as it prioritizes T cell engagers
Plus: Ken Mills becomes CEO of Tagworks, and updates from AstronauTx, Trevi, Thrive and Madrigal
BioCentury | Aug 13, 2024
Data Byte
Summer lull as FDA approves only 2 NMEs in July
Total for the year stands at 26, lagging last year
BioCentury | May 6, 2024
Management Tracks
Pfizer taps Citi’s Baum for C-level pipeline management and strategy role
Plus: Radiotherapy play Ratio gets new COO, CFO; and updates from Araceli, Kezar and Hercules
BioCentury | Jan 19, 2023
Deals
Building dermatology franchise, Sun buys Concert in latest CVR deal
With cash running short, 17-year-old Concert accepts offer for $576M up front as it finally neared commercial stage
BioCentury | Aug 2, 2022
Finance
Aug. 1 Quick Takes: Qiming, Quan lead $120M series B for OriCell
Plus Concert preps JAK1/2 NDA and updates from Otonomy, Stealth and more
BioCentury | Jul 5, 2022
Data Byte
Follow-ons perk up in June, but still well shy of last year’s haul
Ten biotechs raised almost $1 billion in follow-ons in June 2022
BioCentury | May 24, 2022
Product Development
May 23 Quick Takes: priority review for ImmunoGen’s ovarian cancer ADC
Plus Concert meets in Phase III and updates from Sino, Centaurus, Ocugen and more
BioCentury | Feb 2, 2021
Product Development
Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas
Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the
BioCentury | Jan 30, 2020
Financial News
Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE
Items per page:
1 - 10 of 98